Phase II Multicenter Trial of THP-COP Combination Chemotherapy in Stage II/III/IV Intermediate- and High-Grade Non-Hodgkin's Lymphoma: Korean Malignant Lymphoma Study Group.
- Author:
Hong Suk SONG
1
;
Sam Yong KIM
;
Si Young KIM
;
Hyo Jin KIM
;
Wan Kyu EO
;
Do Youn OH
;
Soon Nam LEE
;
Chang Yeol YIM
;
Young Sun HONG
Author Information
1. Department of Internal Medicine, Keimyung University, Korea.
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Chemotherapy;
Non-Hodgkin's lymphoma
- MeSH:
Alopecia;
Anemia;
Aspartate Aminotransferases;
Cyclophosphamide;
Disease-Free Survival;
Doxorubicin;
Drug Therapy;
Drug Therapy, Combination*;
Humans;
Incidence;
Korea;
Lymphoma*;
Lymphoma, Non-Hodgkin*;
Neutropenia;
Prednisolone;
Survival Rate;
Thrombocytopenia;
Vincristine;
Vomiting
- From:Korean Journal of Hematology
1999;34(3):453-460
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: THP-adriamycin ia a tetrahydropyranyl derivative of adriamycin with compatible anti-lymphoma effect but fewer side effects, especially cardiac, nausea/vomiting and alopecia. So we performed a multicenter study of 4-drug combination chemotherapy, THP-COP regimen for patients with non-Hodgkin's lymphoma to evaluate the response rate, survival time and toxicity by Malignant Lymphoma Study Group in Korea. METHODS: Between June 1996 and Feb. 1997, previously untreated stage II/III/IV intermediate and high-grade non-Hodgkin's lymphoma patients were treated with a THP-COP regimen including THP-adriamycin 40 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, oncovin 1.4 mg/m2 on day 1, and prednisolone 100 mg PO on day 1-5 with 3 weeks interval. RESULTS: Twenty six patients (89.7%) were evaluable. Patient characteritics include: median age 54.8 years (16-76) and 13 patients were 60 years or old; clinical stage II in 9 patients (34.6%), stage III in 7 patients (26.9%), and stage IV in 10 patients (38.5%). Objective response were 13 CR, 7 PR, 6 PD with 76.9% response rate. Six months and 1 year survival rates and progression-free survival rates were 87.8%, 70.4%, and 85.0%, 60.5% respectively. Grade 3/4 toxicities were anemia in 7.7%, neutropenia in 53.8%, thrombocytopenia in 3.8%, vomiting in 7.7%, alopecia in 7.7% and increased SGOT in 3.8%. Prognostic significance of age and International Prognostic Index were not demonstrated. CONCLUSION: THP-COP combination chemotherapy is active in advanced stage, non-Hodgkin's lymphoma with low incidence of vomiting and alopecia.
